News Releases
Oct 14, 2020
ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Read more
Oct 6, 2020
ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board Read more
Sep 22, 2020
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer Read more
Sep 17, 2020
ALX Oncology Added to Russell 2000® and 3000® Indexes Read more
Sep 8, 2020
ALX Oncology Announces Participation at Upcoming Investor Conferences Read more
Aug 27, 2020
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Read more
Jul 21, 2020
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more
Jul 16, 2020
ALX Oncology Announces Pricing of Initial Public Offering Read more
Jun 12, 2020
ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more
May 29, 2020
ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more